Wednesday - April 30, 2025

LOGIN  |  REGISTER
Recursion
Astria Therapeutics

Procaps to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday

August 31, 2023 | Last Trade: US$1.01 0.00 0.00

MIAMI & BARRANQUILLA, Colombia / Aug 31, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023.

The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results.

To access the call, please use the following information:

Date:

   

Tuesday, September 5, 2023

Time:

   

11:00 a.m. ET

Webcast:

   

Click here to access

Toll Free dial-in number:

   

1-844-204-8586

Toll/International dial-in number:     

   

1-412-317-6346

Conference ID:

   

Procaps Group

The conference call will be broadcast live and available for replay at https://bit.ly/45sB21M and via the investor relations section of Procaps’ website here.

A telephone replay will be available approximately two hours after the call and will run through September 12, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 1873850.

About Procaps Group

Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

For more information, visit Procaps’ investor relations website investor.procapsgroup.com.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page